BCM
CTMX icon

Bronte Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Bronte Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-906,157
Closed -$1.98M – 29
2024
Q1 		$1.98M Sell
906,157
-13,754
-1% -$25.4K 0.16% 30
2023
Q4 		$1.43M Sell
919,911
-5,334
-0.6% -$7.01K 0.13% 30
2023
Q3 		$1.19M Hold
925,245
– – 0.12% 28
2023
Q2 		$1.59M Buy
925,245
+7,491
+0.8% +$12.4K 0.15% 31
2023
Q1 		$1.39M Buy
+917,754
New +$2.07M 0.16% 29

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Bronte Capital Management's CTMX Position: Q2 2024 in Review

Bronte Capital Management sold out of CytomX Therapeutics (CTMX) in Q2 2024, closing a stake of 906,157 shares — an estimated $1.98M sold.

Bronte Capital Management first reported a position in CTMX in Q1 2023 and held it in 5 quarters. The position peaked at $1.98M in Q1 2024. 74 funds tracked by Wall St. Rank hold CTMX as of Q2 2024.

  • Bronte Capital Management reported no remaining CytomX Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Bronte Capital Management sold 906,157 CytomX Therapeutics shares in Q2 2024, an estimated $1.98M.
  • Bronte Capital Management first reported a position in CytomX Therapeutics in Q1 2023 and held it in 5 quarters.
  • Bronte Capital Management's CytomX Therapeutics position peaked at $1.98M in Q1 2024.
  • 74 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2024.

Based on Bronte Capital Management's 13F filing for Q2 2024, filed 7 Aug 2024.